Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 63% of modeled bridge. Risks: Occupancy Rate, Revenue per Bed. Risk-adjusted uplift: $4.9M (vs $7.9M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $3.0M | $3.0M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $2.9M | $82K | $3.0M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $460K | $1.4M | $1.8M | $5.7M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $96K | $96K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 28.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $749K | $1.5M | $2.2M | $3.0M | $3.0M | $3.0M | $3.0M |
| Denial Rate Reduction | $0 | $741K | $1.5M | $2.2M | $3.0M | $3.0M | $3.0M | $3.0M |
| A/R Days Reduction | $0 | $607K | $1.2M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M |
| Clean Claim Rate | $0 | $48K | $96K | $96K | $96K | $96K | $96K | $96K |
| Cumulative | $0 | $2.1M | $4.3M | $6.4M | $7.9M | $7.9M | $7.9M | $7.9M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $7.9M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 9.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 10.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 11.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 12.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 0% before the 6.5x covenant trips. RCM uplift reduces leverage from 99.0x to 99.0x, adding 0.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $-8.9M | — | $-8.9M | -6.0% |
| Year 1 | $-9.2M | +$5.3M | $-3.9M | -2.6% |
| Year 2 | $-9.5M | +$7.9M | $-1.6M | -1.1% |
| Year 3 | $-9.8M | +$7.9M | $-1.9M | -1.3% |
| Year 4 | $-10.0M | +$7.9M | $-2.2M | -1.4% |
| Year 5 | $-10.3M | +$7.9M | $-2.5M | -1.6% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $1.5M | $2.2M | $3.0M | $3.6M |
| Denial Rate Reductio | $1.5M | $2.2M | $3.0M | $3.6M |
| A/R Days Reduction | $911K | $1.4M | $1.8M | $2.2M |
| Clean Claim Rate | $48K | $72K | $96K | $115K |
| Total | $3.9M | $5.9M | $7.9M | $9.5M |
Peer Context — Where This Hospital Sits
Key metrics vs 149 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | -6.0% | -6.9% | 4.8% | 13.3% | P28 |
| Net-to-Gross | 17.2% | 13.5% | 18.9% | 28.1% | P42 |
| Occupancy | 36.9% | 49.4% | 65.1% | 75.3% | P9 |
| Rev/Bed | $720K | $608K | $1.2M | $1.5M | P30 |
| Exp/Bed | $763K | $616K | $1.0M | $1.4M | P32 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.